TY - JOUR
T1 - Diagnostic performance and clinical utility of referral rules to identify primary care patients at risk of an inflammatory rheumatic disease
AU - van Delft, Elke Theodora Antonia Maria
AU - Lopes Barreto, Deirisa
AU - van der Helm-van Mil, Annette Helena Maria
AU - Alves, Celina
AU - Hazes, Johanna Maria Wilhelmina
AU - Kuijper, Tjallingius Martijn
AU - Weel-Koenders, Angelique Elisabeth Adriana Maria
N1 - Publisher Copyright:
© 2021 American College of Rheumatology.
PY - 2022/12
Y1 - 2022/12
N2 - Objective: To determine the diagnostic performance and clinical utility of the Rotterdam Early Arthritis Cohort (REACH) and the Clinical Arthritis Rule (CARE) referral rules in an independent population of unselected patients from primary care. Methods: This study consisted of adults who were suspected of the need for referral to a rheumatologist by their general practitioner. Diagnostic accuracy measures and a net benefit approach were used to compare both rules to usual care for recognizing inflammatory arthritis and inflammatory rheumatic diseases (IRDs). Using the least absolute shrinkage and selection operator method and cross-validation we created an optimal prediction rule for IRD. Results: This study consisted of 250 patients, of whom 42 (17%) were diagnosed with inflammatory arthritis and 55 (22%) with an IRD 3 months after referral. Considering inflammatory arthritis, the area under the receiver operating characteristic curve (AUC) was 0.72 (95% confidence interval [95% CI] 0.64–0.80) for REACH and 0.82 (95% CI 0.75–0.88) for CARE. Considering IRD, the AUC was 0.66 (95% CI 0.58–0.74) for REACH and 0.76 (95% CI 0.69–0.83) for CARE. CARE was of highest clinical value when compared to usual care. The composite referral rule for IRD of 10 parameters included sex, age, joint features, acute onset of symptoms, physical limitations, and duration of symptoms (AUC 0.82 [95% CI 0.75–0.88]). Conclusion: Both validated rules have a net benefit in recognizing inflammatory arthritis as well as IRD compared to usual care, but CARE shows superiority over REACH. Although the composite referral rule indicates a greater diagnostic performance, external validation is needed.
AB - Objective: To determine the diagnostic performance and clinical utility of the Rotterdam Early Arthritis Cohort (REACH) and the Clinical Arthritis Rule (CARE) referral rules in an independent population of unselected patients from primary care. Methods: This study consisted of adults who were suspected of the need for referral to a rheumatologist by their general practitioner. Diagnostic accuracy measures and a net benefit approach were used to compare both rules to usual care for recognizing inflammatory arthritis and inflammatory rheumatic diseases (IRDs). Using the least absolute shrinkage and selection operator method and cross-validation we created an optimal prediction rule for IRD. Results: This study consisted of 250 patients, of whom 42 (17%) were diagnosed with inflammatory arthritis and 55 (22%) with an IRD 3 months after referral. Considering inflammatory arthritis, the area under the receiver operating characteristic curve (AUC) was 0.72 (95% confidence interval [95% CI] 0.64–0.80) for REACH and 0.82 (95% CI 0.75–0.88) for CARE. Considering IRD, the AUC was 0.66 (95% CI 0.58–0.74) for REACH and 0.76 (95% CI 0.69–0.83) for CARE. CARE was of highest clinical value when compared to usual care. The composite referral rule for IRD of 10 parameters included sex, age, joint features, acute onset of symptoms, physical limitations, and duration of symptoms (AUC 0.82 [95% CI 0.75–0.88]). Conclusion: Both validated rules have a net benefit in recognizing inflammatory arthritis as well as IRD compared to usual care, but CARE shows superiority over REACH. Although the composite referral rule indicates a greater diagnostic performance, external validation is needed.
UR - http://www.scopus.com/inward/record.url?scp=85135183125&partnerID=8YFLogxK
U2 - 10.1002/acr.24789
DO - 10.1002/acr.24789
M3 - Article
C2 - 34553506
SN - 2151-464X
VL - 74
SP - 2100
EP - 2107
JO - Arthritis Care & Research
JF - Arthritis Care & Research
IS - 12
ER -